Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma
The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.
Primary source
ClinicalTrials.gov registry record, November 12, 2026
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
Read the source: A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation